Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Conference News TCT 2024

CONFIRM2 Shows Power of AI-QCT to Use Plaque Features to Predict CAD Events

Yael L. Maxwell

November 01, 2024

News Conference News TCT 2024

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

Caitlin E. Cox

October 28, 2024

News Conference News TCT 2024

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

Michael O'Riordan

October 28, 2024

News Daily News

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Michael O'Riordan

September 20, 2024

News Conference News ESC 2024

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

Todd Neale

September 09, 2024

News Conference News ESC 2024

NOTION-3: PCI Before TAVI Lowers MACE Risks in Patients With Significant CAD

Michael O'Riordan

September 01, 2024

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2024

Shelley Wood

May 31, 2024

News Daily News

With ANOCA, Better to Test Coronary Function in Multiple Vessels

Caitlin E. Cox

May 29, 2024

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

News Conference News EuroPCR 2024

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

Caitlin E. Cox

May 15, 2024

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

L.A. McKeown

May 01, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Opinion CV Team Dispatch

April 2024 Dispatch for the CV Team

L.A. McKeown

April 01, 2024

News Daily News

Risk Factor Control Worse in Women Than Men in ISCHEMIA Trial

Todd Neale

March 04, 2024

News Daily News

Even After Multivessel or LM PCI, Routine Stress Testing Adds Nothing

Yael L. Maxwell

March 01, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

Advertisement

CONFIRM2 Shows Power of AI-QCT to Use Plaque Features to Predict CAD Events

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

NOTION-3: PCI Before TAVI Lowers MACE Risks in Patients With Significant CAD

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

TCTMD’s Top 10 Most Popular Stories for May 2024

With ANOCA, Better to Test Coronary Function in Multiple Vessels

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

May 2024 Dispatch for the CV Team

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

April 2024 Dispatch for the CV Team

Risk Factor Control Worse in Women Than Men in ISCHEMIA Trial

Even After Multivessel or LM PCI, Routine Stress Testing Adds Nothing

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content